Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2010
08/12/2010US20100204227 Isoindoline compounds and methods of their use
08/12/2010US20100204223 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof
08/12/2010US20100204221 Pyrrolopyrimidinyl axl kinase inhibitors
08/12/2010US20100204219 Aromatic 1,4-di-carboxylamides and their use
08/12/2010US20100204217 Treatment for leukemia and idiopathic aplastic anemia
08/12/2010US20100204213 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
08/12/2010US20100204212 Fused heterocyclic compounds useful as kinase modulators
08/12/2010US20100204197 Pyrrolopyrimidines
08/12/2010US20100204196 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer
08/12/2010US20100204193 Metal complexes incorporated within biodegradable nanoparticles and their use
08/12/2010US20100204184 Phosphonates useful as modulators of T-gamma-9-delta-2 activity
08/12/2010US20100204182 Ectonucleotidase inhibitors
08/12/2010US20100204180 Proteasome inhibitors
08/12/2010US20100204175 Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases
08/12/2010US20100204172 Inactivators of o6-alkylguanine-dna alkyltransferase
08/12/2010US20100204170 Heterobifunctional pan-selectin inhibitors
08/12/2010US20100204169 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
08/12/2010US20100204160 Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof
08/12/2010US20100204158 Combination of splenopentin and thymopentin and the use thereof in medicine
08/12/2010US20100204157 Use of a peptide as a therapeutic agent
08/12/2010US20100204156 Use of thymopentin as a therapeutic agent
08/12/2010US20100204155 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
08/12/2010US20100204154 Use of the peptide rfmwmr as a therapeutic agent
08/12/2010US20100204153 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
08/12/2010US20100204152 Use of gluten exorphin c : as a therapeutic agent
08/12/2010US20100204151 Use of a peptide as a therapeutic agent
08/12/2010US20100204150 Use of a peptide as a therapeutic agent
08/12/2010US20100204149 Use of octreotide as a therapeutic agent
08/12/2010US20100204148 (d-leu7 ) -histrelin as a therapeutic agent
08/12/2010US20100204145 Use of a peptide as a therapeutic agent
08/12/2010US20100204144 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
08/12/2010US20100204143 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
08/12/2010US20100204142 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
08/12/2010US20100204141 Use of bpp-b as a therapeutic agent
08/12/2010US20100204140 Use of a peptide as a therapeutic agent
08/12/2010US20100204139 Use of gonadorelin as a therapeutic agent
08/12/2010US20100204138 Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
08/12/2010US20100204136 Use of a peptide as a therapeutic agent
08/12/2010US20100204135 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
08/12/2010US20100204134 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent
08/12/2010US20100204132 THERAPEUTIC USES OF PEPTIDES YSAYPDSVPMMS and WMNSTGFTKVCGAPPC
08/12/2010US20100204131 Use of a peptide as a therapeutic agent
08/12/2010US20100204130 Use of human neuropeptide as a therapeutic agent
08/12/2010US20100204129 Use of a peptide as a therapeutic agent
08/12/2010US20100204125 Genetic alterations associated with cancer
08/12/2010US20100204124 Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
08/12/2010US20100204118 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
08/12/2010US20100204117 Cgrp as a therapeutic agent
08/12/2010US20100204116 Use of calcitonin as anti-angiogenic agent
08/12/2010US20100204115 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents
08/12/2010US20100204114 Use of a galanin peptide as a therapeutic agent
08/12/2010US20100204113 Use of stresscopin-related peptide as a therapeutic agent
08/12/2010US20100204112 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
08/12/2010US20100204111 Astressin and beta- endorphin for use as therapeutic agents
08/12/2010US20100204110 Use of a peptide as a therapeutic agent
08/12/2010US20100204109 Use of c-type natriuretic peptide, alone or in combination with neuropeptide af, as a therapeutic agent
08/12/2010US20100204108 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents
08/12/2010US20100204107 Use of urodilatin as a therapeutic agent
08/12/2010US20100204104 Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
08/12/2010US20100204091 SIVA Ubiquitination and/or Degradation-Related Activity and Modulators Thereof
08/12/2010US20100204090 Use of a peptide as a therapeutic agent
08/12/2010US20100203628 Novel modified galectin 9 proteins and use thereof
08/12/2010US20100203164 Therapeutic Treatment of Cancer and Dysplasia of the Cervix or Vagina Using Estrogen Antagonists
08/12/2010US20100203163 Injectable polymer-lipid blend for localized drug delivery
08/12/2010US20100203162 Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
08/12/2010US20100203153 Sustained-release nanoparticle compositions and methods using the same
08/12/2010US20100203149 Nanoparticles for Cytoplasmic Drug Delivery to Cancer Cells
08/12/2010US20100203147 Viruses for the Treatment of Cellular Proliferative Disorders
08/12/2010US20100203143 Systems and methods for nanomagnetic actuation of molecular cell signaling
08/12/2010US20100203142 Amphiphilic compound assisted nanoparticles for targeted delivery
08/12/2010US20100203136 METHOD FOR DELIVERING A HUMAN CHORIONIC GONADOTROPIN (Hcg) VACCINE FOR LONG-ACTING ANTIBODY PROTECTION
08/12/2010US20100203133 High drug load tablet
08/12/2010US20100203129 Controlled release formulations with continuous efficacy
08/12/2010US20100203114 Micelle encapsulation of therapeutic agents
08/12/2010US20100203113 Wnt signalling inhibitors, and methods for making and using them
08/12/2010US20100203112 Composition of cationic phospholipid nanoparticles for effective delivery of nucleic acids
08/12/2010US20100203110 Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production
08/12/2010US20100203109 Methods and Compositions for Treating Melanoma
08/12/2010US20100203086 Attack of tumor cells with missing, low or aberrant mhc expression by combining non mhc-restricted t-cells/nk-cells and mhc-restricted cells
08/12/2010US20100203083 Mutated structural protein of a parvovirus
08/12/2010US20100203080 Mixture of Peptides Derived from E6 and/or E7 Papillomavirus Proteins and Uses Thereof
08/12/2010US20100203066 Polymeric linkers containing pyridyl disulfide moieties
08/12/2010US20100203065 Human liver regeneration associated protein and the use thereof
08/12/2010US20100203060 Inhibitors for growth hormone and related hormones, and methods of use thereof
08/12/2010US20100203056 Anti-pd-l1 antibodies and their use to enhance t-cell function
08/12/2010US20100203054 Wnt Proteins and Detection and Treatment of Cancer
08/12/2010US20100203048 Methods of using corticotropin-releasing factor for the use of the treatment of cancer
08/12/2010US20100203043 Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr)
08/12/2010US20100203042 Recombinant anti-vla4 antibody molecules
08/12/2010US20100203041 Antibodies to egfl7 and methods for their use
08/12/2010US20100203039 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
08/12/2010US20100203036 Targets for tumor growth inhibition
08/12/2010US20100203035 B7-h3 in cancer
08/12/2010US20100203024 Sickled Erythrocytes, Nucleated Precursors & Erythroleukemia Cells for Targeted Delivery of Oncolytic Viruses, Anti-tumor Proteins, Plasmids, Toxins, Hemolysins & Chemotherapy
08/12/2010US20100203012 Iap bir domain binding compounds
08/12/2010US20100203010 Modulation of tumor microenvironment
08/12/2010US20100203007 Novel benzodiazepine derivatives
08/12/2010US20100203005 Transdermal compositions
08/12/2010US20100202974 Nano-scale contrast agents and methods of use
08/12/2010US20100202967 Fibrin binding pepetide conjugates for diagnostic and therapeutic applications
1 ... 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 ... 2211